MT Newswires
Galectin Therapeutics Insider Sold Shares Worth $1,055,311, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
5/10
- Home
- GALT
as of 12-12-2025 11:00am EST
$5.88
+$0.17
+2.98%
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Chart Type:
Time Range:
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NORCROSS |
| Market Cap: | 232.3M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 440.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.73 - $6.66 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered GALT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 16 hours ago
AI Recommendation
hold
Model Accuracy: 72.11%
72.11%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Galectin Therapeutics Inc. (GALT)
Shlevin Harold H.
Sell
Director
GALT Dec 9, 2025
Avg Cost/Share
$6.27
Shares
16,790
Total Value
$105,206.14
Owned After
11,206
SEC Form 4
Shlevin Harold H.
Sell
Director
GALT Dec 8, 2025
Avg Cost/Share
$5.98
Shares
159,000
Total Value
$950,105.00
Owned After
11,206
10X Fund, L.P.
Sell
10% Owner
GALT Dec 3, 2025
Avg Cost/Share
$5.73
Shares
120,000
Total Value
$687,600.00
Owned After
5,682,207
SEC Form 4
10X Fund, L.P.
Sell
10% Owner
GALT Dec 2, 2025
Avg Cost/Share
$5.47
Shares
30,000
Total Value
$164,100.00
Owned After
5,682,207
SEC Form 4
LEWIS JOEL
Sell
President and CEO
GALT Nov 18, 2025
Avg Cost/Share
$6.15
Shares
6,783
Total Value
$41,722.91
Owned After
832,592
SEC Form 4
CALLICUTT JACK W
Sell
Chief Financial Officer
GALT Nov 18, 2025
Avg Cost/Share
$6.22
Shares
46,310
Total Value
$288,187.13
Owned After
7,614
LEWIS JOEL
Sell
President and CEO
GALT Nov 17, 2025
Avg Cost/Share
$6.04
Shares
15,680
Total Value
$94,642.91
Owned After
832,592
SEC Form 4
CALLICUTT JACK W
Sell
Chief Financial Officer
GALT Nov 17, 2025
Avg Cost/Share
$6.03
Shares
31,610
Total Value
$190,662.04
Owned After
7,614
Jamil Khurram
Sell
Chief Medical Officer
GALT Nov 13, 2025
Avg Cost/Share
$5.47
Shares
121,117
Total Value
$662,509.99
Owned After
4,479
10X Fund, L.P.
Sell
10% Owner
GALT Nov 11, 2025
Avg Cost/Share
$5.25
Shares
40,000
Total Value
$210,000.00
Owned After
5,682,207
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Shlevin Harold H. | GALT | Director | Dec 9, 2025 | Sell | $6.27 | 16,790 | $105,206.14 | 11,206 | |
| Shlevin Harold H. | GALT | Director | Dec 8, 2025 | Sell | $5.98 | 159,000 | $950,105.00 | 11,206 | |
| 10X Fund, L.P. | GALT | 10% Owner | Dec 3, 2025 | Sell | $5.73 | 120,000 | $687,600.00 | 5,682,207 | |
| 10X Fund, L.P. | GALT | 10% Owner | Dec 2, 2025 | Sell | $5.47 | 30,000 | $164,100.00 | 5,682,207 | |
| LEWIS JOEL | GALT | President and CEO | Nov 18, 2025 | Sell | $6.15 | 6,783 | $41,722.91 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Nov 18, 2025 | Sell | $6.22 | 46,310 | $288,187.13 | 7,614 | |
| LEWIS JOEL | GALT | President and CEO | Nov 17, 2025 | Sell | $6.04 | 15,680 | $94,642.91 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Nov 17, 2025 | Sell | $6.03 | 31,610 | $190,662.04 | 7,614 | |
| Jamil Khurram | GALT | Chief Medical Officer | Nov 13, 2025 | Sell | $5.47 | 121,117 | $662,509.99 | 4,479 | |
| 10X Fund, L.P. | GALT | 10% Owner | Nov 11, 2025 | Sell | $5.25 | 40,000 | $210,000.00 | 5,682,207 |
Latest Galectin Therapeutics Inc. News
GALT Breaking Stock News: Dive into GALT Ticker-Specific Updates for Smart Investing
Compare GALT vs Leading Stocks
See how GALT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GALT Galectin Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.